Morning, Tuesday, 16th July 2019
THIS EVENT IS CPD CERTIFIED
This seminar will be a timely opportunity to discuss the key issues for biosimilar use in the NHS.
Delegates will consider the progress of biosimilar use in the NHS and the role of Regional Medicines Optimisation Committees in coordinating uptake.
It follows NHS England’s commitment to reduce spending on medicines by £300m by 2021 through increased use of biosimilars, as outlined in the Commissioning framework for biological medicines.
They will consider the priorities for commissioners in reducing spending on medicines and addressing unwarranted variation in biosimilar use, including the impact of prescribing incentive schemes such as gain share agreements.
Further discussion is expected on how engagement with clinical staff can be improved as well as improving patient awareness of biosimilars, and how best to inform patients and include them in decisions around switching treatments.
Following the inclusion of biosimilars in the new Voluntary Scheme for Branded Medicines Pricing and Access, attendees will also assess whether biosimilar prices are subject to market competition and the impact of payment mechanisms and price control on market access of new biosimilars.
Further sessions consider priorities for encouraging the development of new biosimilars in the UK with the increased investment through the Life Sciences Sector Deal and the next steps for promoting the uptake of new biosimilars in the NHS.
The seminar follows the announcement of the new Accelerated Access Collaborative (AAC), and delegates will consider what support can be provided by the AAC to pharmaceutical companies bringing new products to the market, including accelerating the regulatory process and clarifying the evidence required to evaluate cost-effectiveness.
The agenda also includes sessions on the regulation of biosimilars and the future relationship between the European Medicines Agency and the MHRA, and provides attendees with an opportunity to discuss how biosimilars should be regulated in the UK after Brexit.